Two-year study finds sustained visual acuity gains from Eylea treatment

Research investigating the safety and effectiveness of Eylea treat and extend dosing regimens has found improvements in visual acuity were largely maintained at the end of two years.

The treat and extend programme means clinicians can extend their patients’ dosing intervals by two, four and 12-week increments depending on how long a patient has been on the therapy.

During the trial, patients with wet age-related macular degeneration (AMD) received fewer than four injections on average during their second year of treatment.

The study results were presented at the Congress of European Society of Retina Specialists in Vienna, Austria.

Bayer senior medical adviser, Dr Nitin Jain, highlighted that the ability to tailor dosing regimes for individual wet AMD offers an important clinical benefit.

“More than four in 10 patients were treated with a four-monthly dosing interval at the end of the second year of the study,” he shared.